While molluscum is most common in children, it can still occur in teens and adults
- Up to 10% of molluscum cases are among teens and adults1
- In teens and adults, molluscum bumps can appear anywhere on the skin but are most commonly found in the bathing trunk area (lower abdomen, upper thighs, pubic area, anus, and genital region)2-4
Not an actual patient.
Molluscum spread in teens and adults2-5
Sharing personal care items such as razors, brushes, unwashed clothing, towels, bath sponges, or bar soap
Swimming in community pools
Contact with infected gym equipment or mats
Skin-to-skin contact—direct contact with infected skin, which can be either sexual or non-sexual, is the most common way to spread molluscum
Certain people may be at higher risk of contracting the molluscum virus
People who are immunocompromised or who have atopic dermatitis
The impact of molluscum on teens and adults2-4
Lesions may take months to years to resolve
Spread to other areas of the body
Ongoing discomfort, including pain and itching
Embarrassment about lesions, especially in the anogenital region
Fear of transmission to others, including sexual partners
Time away from work or school for multiple doctor visits and cost of additional copays
Not an actual patient.
Preventing the spread of molluscum3,6,7
Patients with molluscum can be advised to do the following:
- Wash hands thoroughly after touching molluscum lesions
- Do not scratch or pick at the molluscum lesions
- Avoid shaving or waxing the infected area
- Avoid sharing personal items, such as towels, bedding, or unwashed clothing
- Consider covering the bumps if swimming
- Refrain from sexual contact until a doctor is consulted
ZELSUVMI is FDA-approved for the treatment of molluscum in teens and adults8-10
ZELSUVMI was studied in patients aged 1 to 49 years
- Proven efficacy and established safety profile across study participants
- In ZELSUVMI clinical trials, approximately 100 patients were teens or adults
INDICATION
ZELSUVMI is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 1 year of age and older.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Application site reactions, including allergic contact dermatitis, have occurred in patients treated with ZELSUVMI. Suspect allergic contact dermatitis in the event of pain, pruritus, swelling, or erythema at the application site lasting longer than 24 hours. If allergic contact dermatitis occurs, discontinue ZELSUVMI and initiate appropriate therapy.
ADVERSE REACTIONS
The most commonly reported adverse reactions (incidence ≥1%) are application site reactions, including pain (such as burning or stinging sensations, 18.7%), erythema (11.7%), pruritus (5.7%), exfoliation (5.0%), dermatitis (4.9%), swelling (3.5%), erosion (1.6%), discoloration (1.5%), vesicles (1.5%), irritation (1.2%), and infection (1.1%). Other adverse reactions include pyrexia (2.2%), vomiting (1.3%), and upper respiratory tract infection (1.2%).
USE IN SPECIFIC POPULATIONS
Pregnancy: There are no available data with use of ZELSUVMI in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Lactation: There are no data on the presence of berdazimer in human or animal milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ZELSUVMI and potential adverse effects on the breastfed child.
Pediatric: The safety and effectiveness of ZELSUVMI have not been established in pediatric patients younger than 1 year of age.
To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may request medical information and report adverse events or product complaints to Pelthos Inc. by calling 1-855-330-7546 or sending an email to medinfo@pelthos.com.
Please see the full Prescribing Information and Instructions for Use for ZELSUVMI.
References: 1. Han H, Smythe C, Yousefi an F, Berman B. Molluscum contagiosum virus evasion of immune surveillance: a review. J Drugs Dermatol. 2023;22(2):182-189. 2. Meza-Romero R, Navarrete-Dechent C, Downey C. Molluscum contagiosum: an update and review of new perspectives in etiology, diagnosis, and treatment. Clin Cosmet Investig Dermatol. 2019;12:373-381. 3. Hebert AA, Bhatia N, Del Rosso JQ. Molluscum contagiosum: epidemiology, considerations, treatment options, and therapeutic gaps. J Clin Aesthet Dermatol. 2023;16(8 suppl 1):S4-S11. 4. Leung AKC, Barankin B, Hon KLE. Molluscum contagiosum: an update. Recent Pat Inflamm Allergy Drug Discov. 2017;11(1):22-31. 5. Schaffer JV, Berger EM. Molluscum contagiosum. JAMA Dermatol. 2016;152(9):1072. 6. Molluscum contagiosum: overview. American Academy of Dermatology. Accessed July 21, 2025. https://www.aad.org/public/diseases/a-z/molluscum-contagiosum-overview 7. Edwards S, Boffa MJ, Janier M, et al. 2020 Eurpean guideline on the management of genital molluscum contagiosum. JEADV. 2020;35:17-26. 8. ZELSUVMI™ (berdazimer) topical gel, Prescribing Information. LNHC, Inc., Durham, NC; 2024. 9. Browning JC, Enloe C, Cartwright M, et al. Efficacy and safety of topical nitric oxide-releasing berdazimer gel in patients with molluscum contagiosum: a phase 3 randomized clinical trial. JAMA Dermatol. 2022;158(8):871-878. 10. Sugarman JL, Herbert A, Browning JC, et al. Berdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials. J Am Acad Dermatol. 2024;90(2):299-308.